Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 mai 2025 03h00 HE | Source: Enara bio

Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs

Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a...
03 oct. 2024 03h00 HE | Source: Enara bio

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio’s EDAPT®...
04 janv. 2024 08h00 HE | Source: Enara bio

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicityBoehringer...
01 nov. 2023 08h00 HE | Source: Enara bio

Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium

Event brings together leading academics, industry representatives and investors to share progress and discuss future directions in dark genome researchMeeting aims to achieve a better understanding of...